| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Sección de Alergología, Hospital Universitario Dr. Peset, and Universidad de Valencia, Valencia, Spain.
Correspondence to: Luis Prieto, PhD, Sección de Alergología, Hospital Universitario Dr. Peset, C/ Gaspar Aguilar 90, 46017 Valencia, Spain; e-mail: prieto_jes@gva.es
Objectives: To investigate the utility of the determination of airway responsiveness to inhaled adenosine 5'-monophosphate (AMP) and exhaled nitric oxide (ENO) levels as markers for safely reducing the dose of inhaled corticosteroids (ICS) in patients with asthma well controlled with a moderately high ICS dose.
Methods: A total of 37 patients with asthma well controlled for at least 3 months by treatment with a moderately high ICS dose (beclomethasone dipropionate, 500 to 1,000 µg or equivalent daily) were included in the study. Patients were treated for a 2-week run-in (baseline) period with their usual dose of ICS. For the next 12 weeks, patients were treated with ICS at half the previous dose, maintaining the same inhalation device. At the end of the baseline period and after 2 weeks, 8 weeks, and 12 weeks of treatment with a reduced dose of ICS, measurements were made in the following order: ENO, spirometry, and AMP challenge. Furthermore, patients completed a diary twice daily recording peak expiratory flow, daytime and nighttime symptoms, and use of rescue albuterol.
Results: Ten patients had an asthma exacerbation. Using a Kaplan-Meier survival analysis, the significant predictors of a failure of ICS reduction were having both bronchoconstriction in response to AMP and ENO levels 
15 parts per billion (ppb) at baseline (p = 0.006), as well as having both bronchoconstriction in response to AMP and ENO levels 20 ppb at baseline (p = 0.033). Having a decrease in the provocative concentration of AMP causing a 20% fall in FEV1 of at least one doubling concentration 2 weeks after the dose of ICS was halved was a borderline significant predictor for failure of ICS reduction (p = 0.062).
Conclusion: These observations suggest that in asthmatic patients well controlled with ICS, the determination of AMP responsiveness and ENO levels may be useful to identifying those subjects whose condition will or will not deteriorate when the dose of ICS is reduced.
Key Words: adenosine 5'-monophosphate • airway responsiveness • inhaled corticosteroids • nitric oxide
This article has been cited by other articles:
|
|
 |
|
  K. G. Lim and C. Mottram The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice Chest, May 1, 2008; 133(5): 1232 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Prieto, I. Reig, R. Rojas, A. Ferrer, and J. Domenech The effect of challenge method on sensitivity and reactivity to adenosine 5'-monophosphate in subjects with suspected asthma. Chest, November 1, 2006; 130(5): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Roman, H. N. Rivera, S. Roser-Page, S. V. Sitaraman, and J. D. Ritzenthaler Adenosine induces fibronectin expression in lung epithelial cells: implications for airway remodeling Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L317 - L325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Spicuzza, G. Di Maria, and R. Polosa Protective effect on AMP airway responsiveness after a single dose of fluticasone Eur. Respir. J., October 1, 2004; 24(4): 711 - 712. [Full Text] [PDF]
|
|
|
|
|
|
L. Proietti, A. Di Maria, and R. Polosa Monitoring the Adjustment of Antiasthma Medications With Adenosine Monophosphate Bronchoprovocation Chest, October 1, 2004; 126(4): 1384 - 1385. [Full Text] [PDF]
|
|
|
|
|
|
L. Prieto Monitoring the Adjustment of Antiasthma Medications With Adenosine Monophosphate Bronchoprovocation Chest, October 1, 2004; 126(4): 1385 - 1385. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
